摘要
新型抗肿瘤疗法大大提高了癌症的存活率; 然而,他们正在引入新形式的心肌病,这通常可以限制适当的癌症治疗。 因此,需要新的心脏保护疗法,以改善癌症患者的临床结果。 为了测试新的治疗策略,对化学疗法诱发的心肌病的适当实验模型的需求越来越多。 诱导的多能干细胞和人类胚胎干细胞(hESC)来源的心肌细胞可用作替代体外模型,用于研究化疗诱发型心肌病的机制。 在本综述中,我们讨论了使用iPS-和hESC衍生的心肌细胞来评估额外的药物靶点和预测化疗引起的心脏毒性。
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
图形摘要
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
摘要: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Biochemical and Docking Analysis of Substrate Interactions with Polyisoprenylated Methylated Protein Methyl Esterase
Current Cancer Drug Targets Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Current Gene Therapy Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry The Complex Biology of FOXO
Current Drug Targets mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design